araag2/HINT huggingface dataset:
Clinical trial NCT02639052 (phase 1/phase 2, status: completed)
Conditions: pruritus
ICD codes: L29.0, L29.1, L29.2, L29.8, L29.9, L29.3
Drugs: botox, saline
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Healthy volunteers between 18 and 50 years of age.

          2. Must be in general good health with no disease or physical conditions that would
             impair evaluation of itch and pain perception.

          3. No history of chronic itch or pain.

          4. Must abstain from the use of any systemic or topical anti-histamine, steroid, or pain
             relief medications from the week prior to the study till the completion of the study.

          5. Must abstain from the use of moisturizers on the arm.

        Exclusion Criteria:

          1. Individuals under 18 or over 50 years of age.

          2. Inability to complete the required measures.

          3. The presence of an itchy skin disease.

          4. Diagnosis of diseased that would affect itch or pain perception (e.g. neuropathies).

          5. Currently enrolled in any investigational study in which the subject is receiving any
             type of drug, biological, or non-drug therapy.

          6. Use of oral, topical analgesics, or other medications known to interfere with itch or
             pain perception in the week prior to the study and throughout the study (e.g.
             antihistamines, anesthetics, opioids, neuroleptics, etc.).

          7. Use of emollients on the arms a week prior to the study and throughout the study.

          8. Use of anti-depressants, anti-psychotics, and illicit drugs.

          9. Known history of neuropathy, uremia, uncontrolled thyroid disease, and diabetes
             mellitus.

         10. Use of Botulinum toxin in the last year.

         11. Known allergies to Botox.

         12. Pregnant women. (Women of child bearing potential will undergo an human chorionic
             gonadotrophin (hCG) pregnancy test before Botox application).

         13. Hypersensitivity to any botulinum toxin preparation or to any of the components in the
             formulation.

         14. Infection at the injection site.

         15. Cardiovascular disease.

         16. Neuromuscular disorder (e.g., amyotrophic lateral sclerosis, myasthenia gravis, or
             Lambert-Eaton syndrome).

         17. Compromised respiratory function.

         18. Dysphagia.

         19. History of urinary tract infection.

         20. History of urinary retention.
Clinical trial NCT02639767 (phase 1, status: withdrawn)
Conditions: malignant pleural mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: pemetrexed/cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of malignant pleural mesothelioma at MSKCC

          -  No plans for surgical resection

          -  Stage T1-4, N0-3, M0

          -  No prior radiation therapy to the chest, breast or supraclavicular fossa that would
             limit radiation delivery to the full prescription dose

          -  Prior chemotherapy regimens ≤1

          -  Age ≥18 years

          -  Karnofsky performance status ≥ 80%

          -  Pulmonary function tests as follows: DLCO>50% predicted

          -  Adequate hematologic, hepatic, and renal function as indicated by the following
             laboratory values

               -  Absolute neutrophil count ≥ 1,500/mcL

               -  Platelets ≥ 100,000/mcL

               -  Calculated creatinine clearance (CrCl) ≥ 45mL/min (using Cockcroft & Gault
                  method)

               -  Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless known Gilbert's
                  disease)

               -  AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN

        Exclusion Criteria:

          -  Pregnant or lactating women, or men or women not using effective contraception

          -  Patients with an active infection that requires systemic antibiotics, antiviral, or
             antifungal treatments

          -  Patients with a concurrent active malignancy (with the exception of skin cancer)

          -  Patients with serious unstable medical illness

          -  Patients with idiopathic pulmonary fibrosis

          -  Patients with NYHA heart failure class >2

          -  Patients with only one kidney that is ipsilateral to the mesothelioma

          -  Implanted pacemaker and/or defibrillator ipsilateral to the mesothelioma if it cannot
             be moved

          -  Patients meeting the following exclusion criteria will be excluded from the MRI
             portion only:

          -  Metallic implant, e.g. pacemaker, defibrillator

          -  Unmanageable claustrophobia

          -  High risk for nephrogenic systemic fibrosis
Clinical trial NCT02650973 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: chs-1701, pegfilgrastim
SMILES: CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Adult male or female of ages 18 to 45 inclusive

          2. Body weight > 50 kg (110 lb.) and body mass index between 18 and 28 kg/m2 inclusive

          3. Medically healthy with clinically insignificant findings based on medical history,
             12-lead ECG, and physical examination

          4. Negative urine pregnancy test in women of childbearing potential

        Exclusion Criteria:

          1. Previous exposure to pegfilgrastim or filgrastim

          2. Current or previous cancer, diabetes, or any clinically significant cardiovascular,
             metabolic, endocrine, renal, hepatic, gastrointestinal, hematologic, respiratory,
             dermatological, neurological, gynecologic, psychiatric, or other disorder

          3. History of chronic or acute respiratory illness within the past 3 months

          4. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or
             recreational drugs for the duration of study participation

          5. No prescription or nonprescription drugs during the study

          6. Participation in an investigational clinical study within 30 days prior to screening

          7. History of known clinically significant drug and/or food allergies, including allergic
             reaction to latex
Clinical trial NCT02670941 (early phase 1, status: terminated)
Conditions: chemotherapy symptoms
ICD codes: D61.810, Z51.11, D64.81, D70.1, Z92.21, P04.11, T80.810S
Drugs: ginger, lavender, orange, jojoba
SMILES: CCO
Reason stopped: 
    slow accrual; received grant funding for a similar but different study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Non-pregnant adults between the ages of 21 to 89 years of age with diagnosis of cancer
             and be scheduled to receive at least three more cycles of chemotherapy.

          -  Subjects must have had at least one chemotherapy cycle in their current prescribed
             course and have at least three additional chemotherapy cycles planned.

          -  Day 1 of each chemotherapy cycle must be separated from Day 1 of the next chemotherapy
             cycles by at least 12 days.

          -  All chemotherapy regimens are eligible.

          -  Any number of chemotherapy administrations per week during a chemotherapy treatment
             cycle is allowed.

          -  Subjects agree to discontinue any current aromatherapy usage and only use the study
             aromatherapy for symptom management during the course of the study. NOTE: Patients can
             continue to use scented soaps, lotions, shampoos, body sprays, perfume/cologne,
             candles, or air fresheners that they regularly use.

          -  Subjects must be able to read and understand English, as well as provide informed
             consent in order to participate in this study.

        Exclusion Criteria:

          -  Subjects < 21 years old or > 89 years old are not eligible for participation in this
             study at the University of Rochester.

          -  Pregnant females are ineligible for the study because pregnancy is a contraindication
             for chemotherapy and exposure to essentials oils.

          -  Subjects who are chemotherapy-naïve are ineligible.

          -  Subjects with more than four weeks between chemotherapy treatment cycles are not
             eligible.

          -  Concurrent radiation therapy or interferon treatment is not allowed.

          -  Subjects that have used or are currently using aromatherapy inhalation for symptom
             management are not eligible.

          -  Subjects with any known allergy to ginger, lavender, orange, citrus of any kind,
             jojoba, or essential oils.
Clinical trial NCT02674321 (phase 1, status: completed)
Conditions: tourette syndrome
ICD codes: F95.2
Drugs: sd-809
SMILES: [2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2
Eligibility criteria:

        Inclusion Criteria:

          -  12 to 18 years of age, inclusive, at Screening.

          -  Patient has a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
             (DSM-V) diagnosis of Tourette Syndrome and has manifested motor and phonic tics within
             3 months before the Screening visit

          -  Patient has total tic score of ≥19 on the YGTSS

          -  Tic severity and frequency has been stable for at least 2 weeks before the Screening
             visit

          -  Willing to adhere to medication regimen and to comply with all procedures

          -  Patient is in good general health, as indicated by medical and psychiatric history and
             physical examination

          -  Patient and parent/guardian have provided written, informed consent (and written
             assent, as appropriate)

          -  Female patients of childbearing potential agree to use an acceptable method of
             contraception

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  Patient has a serious untreated or undertreated psychiatric illness

          -  Patient has a history of suicidal ideation or behavior

          -  Patient has received tetrabenazine, neuroleptics, benzodiazepines, topiramate,
             dopamine receptor antagonists within 14 days of Screening or Baseline; or botulinum
             toxin within 3 months of Screening or Baseline

          -  Patient is being treated with deep brain stimulation for control of tics

          -  Patient has a progressive or degenerative neurological disorder or a structural
             disorder of the brain

          -  Patient has participated in an investigational drug or device trial within 30 days of
             Screening

          -  Patient is pregnant or breastfeeding at Screening or Baseline

          -  Patient has a history of alcohol or substance abuse in the previous 12 months, as
             defined in the DSM-V

               -  Additional criteria apply, please contact the investigator for more information
Clinical trial NCT02704494 (early phase 1, status: completed)
Conditions: diabetic nephropathy
ICD codes: E10.21, E11.21, E13.21, E08.21, E09.21
Drugs: resveratrol, placebo, losartan
SMILES: OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (DM)

          -  Controlled blood sugar [fasting blood sugar (FBS) <130mg/dl and glycosylated
             hemoglobin (A1C)<7%

          -  Urine albumin >20mg/lit in two separate occasions during the last 3 months period

          -  Serum creatinin < or = 2mg/dl

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Alcoholism

          -  Liver failure (acute or chronic)

          -  Renal failure: serum creatinin >2mg/dl

          -  Glomerulonephritis

          -  Uncontrolled hypertension

          -  Congestive heart failure

          -  Prostate disease

          -  Malignancy

          -  Bilateral renal artery stenosis

          -  Any systemic disease other than DM

          -  Any infection or rheumatologic disorder

          -  Use of warfarin
Clinical trial NCT02704702 (phase 1, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: fimasartan, rosuvastatin, fimasartan + rosuvastatin
SMILES: CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Caucasian male 19-55 years of age.

          2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.

          3. Medically healthy with no clinically significant medical history.

          4. Understands the study procedures in the Informed consent form (ICF), and be willing
             and able to comply with the protocol.

        Exclusion Criteria:

          1. History or presence of clinically significant medical or psychiatric condition or
             disease.

          2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg) or hepatitis C virus (HCV).

          3. Seated blood pressure is less than 90/60 mmHg or greater than 140/90 mmHg at
             screening.

          4. Plasma donation within 7 days prior to the first dose of study drug.

          5. Participation in another clinical trial within 28 days prior to the first dose of
             study drug(s).
Clinical trial NCT02709850 (phase 1, status: completed)
Conditions: hypertriglyceridemia, familial hypercholesterolemia
ICD codes: E78.01, Z83.42
Drugs: ionis angptl3-lrx, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria for All Cohorts:

          -  Must have given written informed consent and be able to comply with all study
             requirements

          -  Males or females 18 to 65 years, inclusive, at the time of informed consent

          -  Body Mass Index (BMI) ≤ 35.0 kg/m2

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or
             postmenopausal.

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

        Inclusion criteria for Cohorts, A, D, and AA to DD only:

          -  Fasting triglycerides (TG) ≥ 150 mg/dL at Screening

          -  Fasting low density lipoprotein cholesterol (LDL-C) > 70 mg/dL at Screening

        Inclusion criteria for Cohorts B and C only:

          -  Fasting TG 90 - 150 mg/dL at Screening

          -  Fasting LDL-C > 70 mg/dL at Screening

        Inclusion Criteria for Cohort EE Only:

          -  Homozygous FH diagnosis and fasting LDL-C ≥ 190 mg/dL (4.9 mmol/L)

        Inclusion Criteria for Cohort FF Only:

          -  Heterozygous FH diagnosis and fasting LDL-C ≥ 160 mg/dL (4.1 mmol/L)

        Inclusion Criteria for Cohorts EE and FF Only:

          -  Maximally tolerated stable LDL-C lowering agents (stable for at least 12 weeks)

          -  On stable low-fat diet

          -  Stable weight (± 4 kg) for ≥ 6 weeks prior to screening

        Exclusion Criteria for All Cohorts:

          -  Known history or positive test for Human Immunodeficiency Virus (HIV), Hepatitis C
             (HCV), or Hepatitis B (HBV)

          -  Treatment with another Study Drug, biological agent, or device within one-month or
             5-half-lives of screening

          -  Regular use of alcohol within 6 months of screening

          -  Use of concomitant drugs unless authorized by the Sponsor Medical Monitor

          -  Known contraindication and/or allergy to heparin

          -  Smoking > 10 cigarettes a day

          -  Considered unsuitable for inclusion by the Principal Investigator

        Exclusion Criteria for Cohorts EE and FF:

          -  Myocardial infarction, percutaneous transluminal coronary intervention, or coronary
             artery bypass graft surgery within 12 weeks prior to screening, or cerebrovascular
             accident within 24 weeks prior to screening. Participants with adequately treated
             stable angina, per Investigator assessment, may be included

          -  Congestive heart failure defined by NYHA Classes III or IV

          -  Type 2 diabetes mellitus (T2DM) with HbA1c > 8.0%

          -  Prior treatment with gene therapy

          -  Currently receiving apheresis treatments or last apheresis treatment was within 8
             weeks of screening
Clinical trial NCT02711462 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: pf-06687234, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was prematurely terminated on 06 october 2016 due to the potential risk of further
    dosing in healthy subjects
  
Eligibility criteria:

        INCLUSION CRITERIA

          -  Healthy females of non childbearing potential and healthy males

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

          -  Ability to personally sign and date the informed consent document and able to comply
             with schedule of activities

          -  For Single Dose Cohort 7 only, Japanese subjects must have four biological Japanese
             grandparents born in Japan.

        EXCLUSION CRITERIA

          -  Evidence or history of clinically significant health concerns

          -  Treatment with an investigational drug within 30 days

          -  Exposure to any live vaccines within 28 days prior to investigational product
             administration.

          -  History of drug and/ or alcohol abuse and tobacco use equivalent of 5 cigarettes per
             day.

          -  Known history of infection with hepatitis B virus, hepatitis C virus, or human
             immunodeficiency virus

          -  Pregnant female subjects

          -  History of sensitivity to heparin

          -  Unwilling or unable to comply with the Lifestyle Guidelines as stated in the protocol
Clinical trial NCT02713477 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin glargine/ lixisenatide fixed-ratio combination hoe901/ave0010, insulin glargine hoe901, placebo
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria :

          -  Japanese male or female patients with T2DM diagnosed for at least 1 year prior to the
             time of screening as established in the medical history.

          -  Patients aged 20 to 75 years at screening.

          -  Body mass index ≤35 kg/m^2 at screening.

          -  Glycohemoglobin ≥7.0% and ≤10.0% at screening.

          -  Fasting C-peptide ≥0.6 ng/mL at screening.

        Exclusion criteria:

          -  Diabetes other than T2DM.

          -  History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to
             screening.

          -  History of hypoglycemia unawareness.

          -  Hemoglobinopathy or hemolytic anemia.

          -  History of myocardial infarction, stroke, or heart failure, history or presence of
             clinically significant diabetic retinopathy, history or presence of macular edema
             likely to require laser treatment within the study period.

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
             stomach/gastric surgery, inflammatory bowel disease.

          -  Clinically relevant history of gastrointestinal disease associated with prolonged
             nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal
             reflux disease requiring medical treatment.

          -  Personal or family history of medullary thyroid cancer (MTC) or genetic conditions
             that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).

          -  If female, pregnancy or breast-feeding.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT02718495 (phase 1/phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: pti-428, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of CF.

          -  Forced expiratory volume in 1 second (FEV1) 40-90% predicted.

          -  Non-smoker and non-tobacco user for a minimum of 30 days prior to screening and for
             the duration of the study.

        Exclusion Criteria:

          -  Participation in another clinical trial or treatment with an investigational agent
             within 30 days or 5 half-lives, whichever is longer, prior to Study Day 1.

          -  History of cancer within the past five years (excluding cervical CIS with curative
             therapy for at least one year prior to screening and non-melanoma skin cancer).

          -  History of organ transplantation.

          -  Any sinopulmonary infection or CF exacerbation requiring a change or addition of
             medication (including antibiotics) within 1 month of Study Day 1 or any other
             clinically significant infection as determined by the investigator within 1 month of
             Day 1.

          -  History of alcohol or drug abuse or dependence within 12 months of screening as
             determined by the Investigator.

          -  Male and female of child-bearing potential, unless they are using highly effective
             methods of contraception during participation in the clinical study and for 4 weeks
             after termination from study.

          -  Pregnant or nursing women.